3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
5
Gastro-enteropancreatic neuroendocrine tumor
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Temozolomide
2
LY3023414
2
Etoposide
2
thymoglobulin
1
temsirolimus
1
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
amino-acid, glucose, and electrolyte solution
1
Vincristine
1
Vemurafenib
1
Thiotepa
1
Tacrolimus
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled